BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 15866586)

  • 1. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
    Park WI; Kim SS; Chung HR; Shin SY; Lee JY
    Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome.
    Moran C; Renteria JL; Moran S; Herrera J; Gonzalez S; Bermudez JA
    Fertil Steril; 2008 Dec; 90(6):2310-7. PubMed ID: 18163993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach in the evaluation of gonadotropins for the diagnosis of polycystic ovary syndrome.
    Manieri C; Pastorino R; Marolda AR; Musso M; Boggio G; Fornengo R; Tagliabue M; Di Bisceglie C; Camanni F
    Panminerva Med; 1995 Sep; 37(3):115-8. PubMed ID: 8869364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of subcutaneous and intravenous pulsatile gonadotropin releasing hormone in polycystic ovary disease.
    Saffan DS; Seibel MM
    J Reprod Med; 1992 Jun; 37(6):545-51. PubMed ID: 1619610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
    Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
    Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin pulsatility in Cushing's syndrome compared with polycystic ovary syndrome.
    Penezić Z; Zarković M; Vujović S; Cirić J; Beleslin B; Ivović M; Pokrajac A; Drezgić M
    Gynecol Endocrinol; 2005 Mar; 20(3):150-4. PubMed ID: 16019354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
    Kuroda G
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):247-59. PubMed ID: 3111899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.